Research progress of inhaled anti-tuberculous drugs in the treatment of pulmonary tuberculosis

doi:10.11958/20212611

Abstract

Abstract:

Inhalation of antituberculous drugs in the treatment of pulmonary tuberculosis has achieved good results in patients with bronchial tuberculosis. However, the diameter of atomized drug particles is too large and the drug distribution is uneven, so that it can not be used for patients with alveolar tissue tuberculosis. In recent years, with the in-depth development of follow-up drug carriers, it is possible to apply antituberculous drugs to patients with alveolar tissue tuberculosis by inhalation, which have good safety and effectiveness. This paper reviews the research progress of inhaled antituberculous drugs in the treatment of alveolar tissue tuberculosis.

Key words: tuberculosis,pulmonary, antitubercular agents, inhalation, drug delivery

CLC Number:

R446.5

References 35

[1]	中华人民共和国国家卫生和计划生育委员会. 中华人民共和国卫生行业标准:肺结核诊断:WS 288-2017[S]. 北京: 国家卫生和计划生育委员会, 2017:1-4.
	State Health and Family Planning Commission of the People's Republic of China. Diagnosis of pulmonary tuberculosis Health industry Standard of the People's Republic of China:Diagnosis of pulmonary tuberculosis:WS 288-2017[S]. Beijing: National Health and Family Planning Commission, 2017:1-4.
[2]	MIRZAYEV F, VINEY K, LINH N N, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis,2020 update[J]. Eur Respir J, 2021, 57(6):2003300. doi: 10.1183/13993003.03300-2020.
[3]	World Health Organization(WHO). Global Tuberculosis Report 2021[EB/OL]. (2021-10-14)[2021-11-22]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.
[4]	任成山, 林辉, 杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3):269-274.
	REN C S, LIN H, YANG S M. Epidemiological characteristics of tuberculosis and distress and strategies of multidrug resistance[J/CD]. China J Lung Dis(Electronic Edition), 2019, 12(3):269-274. doi: 10.3877/cma.j.issn.1674-6902.2019.03.001.
[5]	MACNEIL A, GLAZIOU P, SISMANIDIS C, et al. Global epidemiology of tuberculosis and progress toward meeting global targets-worldwide,2018[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(11):281-285. doi: 10.15585/mmwr.mm6911a2.
[6]	SHAH I, POOJARI V, MESHRAM H. Multi-drug resistant and extensively-drug resistant tuberculosis[J]. Indian J Pediatr, 2020, 87(10):833-839. doi: 10.1007/s12098-020-03230-1.
[7]	URBANOWSKI M E, ORDONEZ A A, RUIZ-BEDOYA C A, et al. Cavitary tuberculosis:the gateway of disease transmission[J]. Lancet Infect Dis, 2020, 20(6):e117-e128. doi: 10.1016/S1473-3099(20)30148-1.
[8]	BASSETTI M, VENA A, RUSSO A, et al. Inhaled liposomal antimicrobial delivery in lung infections[J]. Drugs, 2020, 80(13):1309-1318. doi: 10.1007/s40265-020-01359-z.
[9]	王思思. 雾化吸入抗菌药物辅助治疗呼吸系统感染性疾病的有效性及安全性的Meta分析[D]. 天津: 天津医科大学, 2020.
	WANG S S. Efficacy and safety of aerosolized inhaled antibacterials in the adjuvant treatment of respiratory infection:A Meta-analysis[D]. Tianjin: Tianjin Medical University, 2020.
[10]	SHAH S, GHETIYA R, SONIWALA M, et al. Development and optimization of inhalable levofloxacin nanoparticles for the treatment of tuberculosis[J]. Curr Drug Deliv, 2021, 18(6):779-793. doi: 10.2174/1567201817999201103194626.
[11]	KHADKA P, HILL P C, ZHANG B, et al. A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment[J]. Int J Pharm, 2020, 587:119602. doi: 10.1016/j.ijpharm.2020.119602.
[12]	MOMIN M, TUCKER I G, DAS S C. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin[J]. Drug Dev Ind Pharm, 2019, 45(7):1205-1213. doi: 10.1080/03639045.2019.1607869.
[13]	HE Y, LIANG Y, HAN R, et al. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy[J]. J Control Release, 2019, 314:48-61. doi: 10.1016/j.jconrel.2019.10.035.
[14]	莫胜林, 蒋忠胜. 气管支气管结核诊治新进展[J]. 重庆医学, 2021, 50(11):1927-1931.
	MO S L, JIANG Z S. New progress in diagnosis and treatment of tracheobronchial tuberculosis[J]. Chongqing Med, 2021, 50(11):1927-1931. doi: 10.3969/j.issn.1671-8348.2021.11.028.
[15]	中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 气管支气管结核诊断和治疗指南(试行)[J]. 中华结核和呼吸杂志, 2012, 35(8):581-587.
	The tuberculosis branch of Chinese Medicine Association, Editorial Committee of Chinese Journal of Tuberculosis and Respiratory Diseases. Guidelines for the diagnosis and treatment of tracheobronchial tuberculosis(trial)[J]. Chin J Tuberc Respir Dis, 2012, 35(8):581-587. doi: 10.3760/cma.j.issn.1001-0939.2012.08.007.
[16]	曾丽娟, 张洁. 抗结核药物不同给药途径的研究进展[J]. 东南国防医药, 2018, 20(5):532-534.
	ZENG L J, ZHANG J. Research progress of different routes of administration of antituberculous drugs[J]. Southeast National Defense Medicine, 2018, 20(5):532-534. doi: 10.3969/j.issn.1672-271X.2018.05.019.
[17]	陈玥龙, 戴枥湾, 李一诗, 等. 气管支气管结核治疗进展[J]. 重庆医科大学学报, 2020, 45(6):714-717.
	CHEN Y L, DAI L W, LI Y S, et al. Progress in treatment of tracheobronchial tuberculosis[J]. Journal of Chongqing Medical University, 2020, 45(6):714-717. doi: 10.13406/j.cnki.cyxb.002368.
[18]	THAKUR A K, CHELLAPPAN D K, DUA K, et al. Patented therapeutic drug delivery strategies for targeting pulmonary diseases[J]. Expert Opin Ther Pat, 2020, 30(5):375-387. doi: 10.1080/13543776.2020.1741547.
[19]	SHARMA S. Emerging treatment trends in pediatric TB[J]. Indian J Tuberc, 2019, 66(1):214-217. doi: 10.1016/j.ijtb.2019.02.010.
[20]	SHARMA S, SINGHAL R, SARIN R, et al. Emerging trends in microbiological diagnostics in children[J]. Indian J Tuberc, 2019, 66(4):549-554. doi: 10.1016/j.ijtb.2019.11.007.
[21]	WYSZOGRODZKA-GAWEł G, DOROżYńSKI P, GIOVAGNOLI S, et al. An inhalable theranostic system for local tuberculosis treatment containing an isoniazid loaded metal organic framework Fe-MIL-101-NH2-from raw mof to drug delivery system[J]. Pharmaceutics, 2019, 11(12):687. doi: 10.3390/pharmaceutics11120687.
[22]	GRIFFITH D E, EAGLE G, THOMSON R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (convert). A prospective,open-label,randomized study[J]. Am J Respir Crit Care Med, 2018, 198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
[23]	BRAUNSTEIN M, HICKEY A J, EKINS S. Why Wait? The case for treating tuberculosis with inhaled drugs[J]. Pharm Res, 2019, 36(12):166. doi: 10.1007/s11095-019-2704-6.
[24]	SANKHE K, KHAN T, BHAVSAR C, et al. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB[J]. Expert Opin Drug Deliv, 2019, 16(5):525-538. doi: 10.1080/17425247.2019.1609937.
[25]	PHAM D D, GRÉGOIRE N, COUET W, et al. Pulmonary delivery of pyrazinamide-loaded large porous particles[J]. Eur J Pharm Biopharm, 2015, 94:241-250. doi: 10.1016/j.ejpb.2015.05.021.
[26]	MEHANNA M M, MOHYELDIN S M, ELGINDY N A. Rifampicin-carbohydrate spray-dried nanocomposite:A futuristic multiparticulate platform for pulmonary delivery[J]. Int J Nanomedicine, 2019, 14:9089-9112. doi: 10.2147/IJN.S211182.
[27]	向海滨. 利福喷丁/聚乳酸-羟基乙酸纳米粒的制备及体外释药特性研究[D]. 新疆: 新疆医科大学, 2020.
	XIANG H B. Preparation of rifapentine loaded poly(lactic-co-glycolic acid) nanoparticles and characteristics of drug release in vitro[D]. Xinjiang: Xinjiang Medical University, 2020.
[28]	ROJANARAT W, NAKPHENG T, THAWITHONG E, et al. Inhaled pyrazinamide proliposome for targeting alveolar macrophages[J]. Drug Deliv, 2012, 19(7):334-345. doi: 10.3109/10717544.2012.721144.
[29]	SRICHANA T, RATANAJAMIT C, JUTHONG S, et al. Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs[J]. Biol Pharm Bull, 2016, 39(11):1815-1822. doi: 10.1248/bpb.b16-00354.
[30]	OLIVEIRA P M, MATOS B N, PEREIRA P, et al. Microparticles prepared with 50-190 kDa chitosan as promising non-toxic carriers for pulmonary delivery of isoniazid[J]. Carbohydr Polym, 2017, 174:421-431. doi: 10.1016/j.carbpol.2017.06.090.
[31]	LUDMYLLA C, SUSANA R, ANA M R, et al. Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment[J]. Drug Dev Ind Pharm, 2019, 45(8):1313-1320. doi: 10.1080/03639045.2019.1608231.
[32]	黄洁云. 载利福喷丁与利奈唑胺聚乳酸-羟基乙酸缓释微球肺部靶向给药系统的研究[D]. 太原: 山西医科大学, 2017.
	HUANG J Y. Study on rifapentine-linezolid-loaded plga microspheres for lung targeting drug delivery[D]. Taiyuan: Shanxi Medical University, 2017.
[33]	SHKURUPY V A, CHERDANTSEVA L A, KOVNER A V, et al. Structural changes in the lungs and liver of mice with experimental tuberculosis treated with liposome-encapsulated dextrazide[J]. Bull Exp Biol Med, 2020, 168(5):654-657. doi: 10.1007/s10517-020-04773-1.
[34]	GRENHA A, ALVES A D, GUERREIRO F, et al. Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin:Therapeutic assessment in a murine model of tuberculosis infection[J]. Eur J Pharm Biopharm, 2020, 147:38-44. doi: 10.1016/j.ejpb.2019.11.009.
[35]	TAN Z M, LAI G P, PANDEY M, et al. Novel approaches for the treatment of pulmonary tuberculosis[J]. Pharmaceutics, 2020, 12(12):1196. doi: 10.3390/pharmaceutics12121196.